Pliant Therapeutics Inc. (NASDAQ:PLRX) does about 405.88K shares in volume on a normal day but saw 13448097 shares change hands in Monday trading. The company now has a market cap of 1.44B USD. Its current market price is $30.28, marking an increase of 34.52% compared to the previous close of $22.51. The 52 week high reached by this stock is $26.25 whilst the lowest price level in 52 weeks is $3.96. The script in recent trading has seen the stock touch a high of $36.50 and a low of $29.94.
Pliant Therapeutics Inc. (PLRX) has a 20-day trading average at $20.76 and the current price is 15.35% off the 52-week high compared with 663.68% distance from its 52-week low. The 50-day simple moving average of the closing price is $19.83 and its 200-day simple moving average is $16.10. If we look at the stock’s price movements over the week, volatility stands at 7.72%, which decreases to 6.48% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 82.75 to suggest the stock is overbought.
12 analysts observing the Pliant Therapeutics Inc. (PLRX) stock have set the 12-month price targets for the company’s shares at between $33.00 and $60.00. The consensus objective for the share price is $41.91, suggesting that the stock has a potential upside of 27.75% over the period. The median price target is 32.71% away from the current levels at $45.00.
FactSet Research has provided data showing that 12 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 11 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 14, 2022 when Stifel initiated the stock to “Buy” and issued a price target of $33. Citigroup initiated its price target at $36.
The current price level is 49.82%, 54.06%, and 89.48% away from its SMA20, SMA50, and SMA200 respectively, with the PLRX price moving below the 50-day SMA on January 23. Pliant Therapeutics Inc. (PLRX) stock is up 29.18% over the week and 58.87% over the past month. Its price is 56.65% year-to-date and 170.36% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2022, with the company’s earnings per share (EPS) of -$0.82 below consensus estimates by -$0.01. The company’s next earnings report is expected on 05/08/2023, with forecasts estimating quarterly EPS at -$0.74 and -$3.02 for whole year. PLRX’s earnings per share are forecast to shrink by -11.40% this year and -4.00% over next year. Expected sales for next quarter are $1.6 million, which analysts say will come at $9.47 million for the current fiscal year and next year at $3.56 million. In addition, estimates put the company’s current quarterly revenue at an average of $1.59 million.
Its 12-month price target is $45.00. To reach the target analysts have set, the stock logically needs to grow 27.75 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $33.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $60.00.
Outstanding shares total 46.80M with insiders holding 6.66% of the shares and institutional holders owning 60.71% of the company’s common stock. The company has a return on investment of -47.30% and return on equity of -52.60%. Price to book ratio is 4.21 and price to sales ratio is 148.31.
According to a U.S. Securities and Exchange Commission filing, Polar Capital Funds Plc – Biotech has added its position in Pliant Therapeutics Inc. (PLRX) to 1,500,000 shares, mirroring a recent increase by 10.05%. Polar Capital Funds Plc – Biotech added 0.14 million shares of Pliant Therapeutics Inc. common stock bringing its total worth to about $29.0 million at the end of recent close, SEC documents show. Polar Capital Funds Plc – Biotech isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 0.16 million shares to end up with 1,256,914 shares worth $24.3 million. Fidelity Growth Company Fund cut their holdings by -2.33% in the company over the course of the most recent quarter. It now holds a 2.51% position in Pliant Therapeutics Inc. thanks to 1.22 million shares amounting to $23.65 million.